Sandoz Inc, a Germany-based company that develops, manufactures, and distributes generic pharmaceutical products, has signed a long-term agreement with Civica Rx, a United States-based non-profit organisation that seeks to make quality generic medicines available and affordable to its hospital members, it was reported on Tuesday.
The contract has been signed to produce and provide critical injectable generic medicines, in order to decrease supply shortages in US hospitals and ensure that acute care settings can deliver optimal patient care.
According to the five-year contract, Sandoz Inc is to provide six injectable medicines, including antibiotics, acid reducers, blood thinners, blood pressure regulators and medicines required in the operating room to Civica's hospitals, which to date include more than 50 health systems, representing 1,200 hospitals and more than 30% of all licensed US hospital beds.
Sandoz is likely to start shipping to Civica later this year.
Amneal's risperidone extended-release injectable suspension approved by US FDA
First FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Viatris' generic iron sucrose injection gains US FDA approval
Newbury Pharmaceuticals gains Finnish approval for generic melatonin
CivicaScript to distribute biosimilar for chronic inflammatory conditions
Mallinckrodt and Endo complete merger
Zenara Pharma's Sertraline Hydrochloride Capsules generic receives US FDA approval
EQT agrees to acquire majority stake in Adalvo
Mallinckrodt receives Irish High Court ruling to combine with Endo Inc
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CivicaScript introduces low-cost multiple sclerosis treatment
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Glenmark Therapeutics launches Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment